RaQualia Pharma Inc. Price (4579.T)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

21,641,457

(0.163)%

RaQualia Performance History

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $362-720
  • Market Cap 8.63B
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Masaki Sudo
  • IPO Date: July, 20, 2011
  • Country: JP
  • Currency: JPY
  • Headquaters: No Data
  • Employees: 67

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation